Dallas, Texas - As heart disease and stroke continue to claim more lives worldwide than all other causes, the American Heart Association is boldly growing beyond borders and its core business to advance health and well-being across the globe. It’s all part of the Association’s new mission: To be a relentless force for a world of longer, healthier lives.

Washington, DC - An investigational oral antibiotic called zoliflodacin was well-tolerated and successfully cured most cases of uncomplicated gonorrhea when tested in a Phase 2 multicenter clinical trial, according to findings published today in the New England Journal of Medicine. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored the clinical study.

Washington, DC - The National Institute on Minority Health and Health Disparities (NIMHD), part of the National Institutes of Health, has selected the third annual awardees of the William G. Coleman Jr., Ph.D., Minority Health and Health Disparities Research Innovation Award. This competitive award program is designed to support one-year innovative research projects contributed by postdoctoral fellows, staff scientists, and staff clinicians within the NIH Intramural Research Program that have the potential for high impact in any area of minority health and health disparities research.

New Orleans, Louisiana - Naval Medical Research Center (NMRC) scientists, in collaboration with Walter Reed Army Institute of Research (WRAIR), have developed a state-of-the-art method to analyze immune response to dengue vaccines by measuring antibody-dependent cellular cytotoxicity (ADCC).

Washington, DC - Friday, the U.S. Food and Drug Administration permitted marketing of two devices that provide real-time location of parathyroid tissue during surgical procedures such as thyroidectomy (surgery to remove all or part of the thyroid) and parathyroidectomy (surgery to remove one or more parathyroid glands).

Washington, DC - Critically ill patients in intensive care units (ICUs) did not benefit from two antipsychotic drugs used to treat delirium, according to a large clinical trial funded by the National Institute on Aging, part of the National Institutes of Health. The multi-site team that conducted the trial found no evidence that treatment with antipsychotic medicines — haloperidol or ziprasidone — affected delirium, survival, length of ICU or hospital stay or safety. The findings from the Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study were published online Oct. 22, 2018 in The New England Journal of Medicine.